Publikationen 2018
278.
Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A.
Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease
Sci Rep. 2018, 8(1):15940.
277.
Huang QF, Van Keer J, Zhang ZY, Trenson S, Nkuipou-Kenfack E, Van Aelst LNL, Yang WY, Thijs L, Wei FF, Ciarka A, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.
Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients
PLoS One. 2018, 13(9):e0204439.
276.
Wallbach M, Zürbig P, Dihazi H, Müller GA, Wachter R, Beige J, Koziolek MJ, Mischak H.
Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension
J Clin Hypertens (Greenwich). 2018, 20(10):1519-1526.
275.
Latosinska A., Frantzi M., Merseburger AS, Mischak H,
Promise and Implementation of Proteomic Prostate Cancer Biomarkers
Diagnostics (Basel). 2018, 8(3):57.
274.
Markoska K, Pejchinovski M, Pontillo C, Zürbig P, Jacobs L, Smith A, Masin-Spasovska J, Stojceva-Taneva O, Polenakovic M, Magni F, Mischak H, Spasovski G.
Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients
Nephrol Dial Transplant. 2018, 33(5):751-759.
273.
Huang QF, Trenson S, Zhang ZY, Van Keer J, Van Aelst LNL, Yang WY, Nkuipou-Kenfack E, Thijs L, Wei FF, Mujaj B, Ciarka A, Droogné W, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.
Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study
Transplant Direct. 2018, 4(5):e346.
272.
Frantzi M, Latosinska A, Kontostathi G, Mischak H.
Clinical Proteomics: Closing the Gap from Discovery to Implementation
Proteomics. 2018, 18(14):e1700463. Epub 2018 Jul 8.
271.
Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
Diabet Med. 2018, 35(10):1375-1382. Epub 2018 Jun 6.
270.
Zhang ZY, Nkuipou-Kenfack E, Yang WY, Wei FF, Cauwenberghs N, Thijs L, Huang QF, Feng YM, Schanstra JP, Kuznetsova T, Voigt JU, Verhamme P, Mischak H, Staessen JA.
Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction
J Am Soc Hypertens. 2018, 12(6):438-447.e4. Epub 2018 Mar 21.
269.
Lygirou V, Latosinska A, Makridakis M, Mullen W, Delles C, Schanstra JP, Zoidakis J, Pieske B, Mischak H, Vlahou A.
Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease
J Transl Med. 2018, 16(1):104.
268.
Currie GE, von Scholten BJ, Mary S, Flores Guerrero JL, Lindhardt M, Reinhard H, Jacobsen PK, Mullen W, Parving HH, Mischak H, Rossing P, Delles C.
Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria
Cardiovasc Diabetol. 2018, 17(1):50.
267.
Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H, Serra AL.
Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
Sci Rep. 2018, 8(1):5584.
266.
Magalhães P, Pontillo C, Pejchinovski M, Siwy J, Krochmal M, Makridakis M, Carrick E, Klein J, Mullen W, Jankowski J, Vlahou A, Mischak H, Schanstra JP, Zürbig P, Pape L.
Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling
Proteomics Clin Appl. 2018, 12(5):e1700163. Epub 2018 Apr 23.
265.
Krochmal M, Schanstra JP, Mischak H.
Urinary peptidomics in kidney disease and drug research
Expert Opin Drug Discov. 2018, 13(3):259-268.
264.
Latosinska A, Frantzi M, Vlahou A, Merseburger AS, Mischak H.
Clinical Proteomics for Precision Medicine: The Bladder Cancer Case
Proteomics Clin Appl. 2018, 12(2). Epub 2017 Oct 25.
263.
Dacheva I, Reich M, Nobl M, Ceglowska K, Wasiak J, Siwy J, Zürbig P, Mischak H, Koch FH, Kopitz J, Kretz FT, Tandogan T, Auffarth GU, Koss MJ.
[Proteome analysis of undiluted vitreous humor in patients with branch retinal vein occlusion]
Ophthalmologe. 2018, 115(3):203-215.
262.
Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.
Urinary CE-MS peptide marker pattern for detection of solid tumors
Sci Rep. 2018, 8(1):5227.
261.
Lindhardt M, Persson F, Oxlund C, Jacobsen IA, Zürbig P, Mischak H, Rossing P, Heerspink HJ.
Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension
Nephrol Dial Transplant. 2018, 33(2):296-303.
260.
Marx D, Metzger J, Pejchinovski M, Gil RB, Frantzi M, Latosinska A, Belczacka I, Heinzmann SS, Husi H, Zoidakis J, Klingele M, Herget-Rosenthal S.
Proteomics and Metabolomics for AKI Diagnosis
Semin Nephrol. 2018, 38(1):63-87.
259.
Pejchinovski M, Siwy J, Mullen W, Mischak H, Petri MA, Burkly LC, Wei R.
Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus
Lupus. 2018, 27(1):6-16. Epub 2017 May 5.
258.
Latosinska A, Hulko M, Speidel R, Mischak H, Storr M, Krause B.
Removal of Cell-Activating Substances Using Dialyzers With Various Permeability Profiles
Artif Organs. 2018, 42(1):78-87. Epub 2017 Jul 26.